Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | FAAH | O00519 | 3/20 | 0.51 |
| ▸ | NAAA | Q02083 | 2/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | MGLL | Q99685 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9615745 | 1.00 | KMT2A (0.55) | KMT2AMEN1FAAHNAAAALOX5 | |
| SCHEMBL25752209 | 1.00 | KMT2A (0.55) | KMT2AMEN1FAAHNAAAALOX5 | |
| SCHEMBL17003978 | 1.00 | KMT2A (0.55) | KMT2AMEN1FAAHNAAAALOX5 | |
| SCHEMBL6269938 | 1.00 | KMT2A (0.55) | KMT2AMEN1FAAHNAAAALOX5 | |
| SCHEMBL10745323 | 1.00 | KMT2A (0.55) | KMT2AMEN1FAAHNAAAALOX5 | |
| SCHEMBL8671910 | 1.00 | KMT2A (0.55) | KMT2AMEN1FAAHNAAAALOX5 | |
| SCHEMBL8587006 | 1.00 | KMT2A (0.55) | KMT2AMEN1FAAHNAAAALOX5 | |
| SCHEMBL10868669 | 1.00 | KMT2A (0.55) | KMT2AMEN1FAAHNAAAALOX5 | |
| SCHEMBL6561471 | 1.00 | KMT2A (0.55) | KMT2AMEN1FAAHNAAAALOX5 | |
| SCHEMBL3420576 | 0.98 | KMT2A (0.56) | KMT2AMEN1FAAHNAAAALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0743956-A4 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORP (US) | 1999-03-24 | — | — | EP | claimed |
| EP-0743956-A1 | PRETARGETING METHODS AND COMPOUNDS | NeoRx (US) | 1996-11-27 | — | — | EP | claimed |
| JP-10001426-A | — | — | None | — | — | JP | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-11236039-B2 | Multi-step process for converting cyclic alkyleneureas into their corresponding alkyleneamines | NOURYON CHEMICALS INTERNATIONAL B.V. (NL) | 2022-02-01 | — | — | US | disclosed |
| EP-0906015-A4 | LIVER RETENTION CLEARING AGENTS | NEORX CORP (US) | 2004-05-12 | — | — | EP | disclosed |
| EP-0914042-A4 | CLUSTER CLEARING AGENTS | NEORX CORP (US) | 2000-10-25 | — | — | EP | disclosed |
| EP-0794788-A4 | HEPATIC-DIRECTED COMPOUNDS AND REAGENTS FOR PREPARATION THEREOF | NEORX CORP (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1997046098-A9 | CLUSTER CLEARING AGENTS | — | 1998-08-06 | — | — | WO | disclosed |
| JP-H101426-A | HAIR TREATMENT COMPOSITION | KAO CORP | 1998-01-06 | — | — | JP | disclosed |
| WO-1997046098-A1 | CLUSTER CLEARING AGENTS | NEORX CORPORATION (US) | 1997-12-11 | — | — | WO | disclosed |
| WO-1997046099-A1 | LIVER RETENTION CLEARING AGENTS | NEORX CORPORATION (US) | 1997-12-11 | — | — | WO | disclosed |
| EP-0794788-A1 | HEPATIC-DIRECTED COMPOUNDS AND REAGENTS FOR PREPARATION THEREOF | NEORX CORPORATION (US) | 1997-09-17 | — | — | EP | disclosed |
| EP-0743956-A1 | PRETARGETING METHODS AND COMPOUNDS | NeoRx (US) | 1996-11-27 | — | — | EP | disclosed |
| WO-1996017613-A1 | HEPATIC-DIRECTED COMPOUNDS AND REAGENTS FOR PREPARATION THEREOF | NEORX CORPORATION (US) | 1996-06-13 | — | — | WO | disclosed |
| US-3932452-A | 1-Arylmethyl-2-imidazolidinones | MORTON-NORWICH PRODUCTS, INC. (US) | 1976-01-13 | — | — | US | disclosed |
| US-3932452-A | 1-Arylmethyl-2-imidazolidinones | MORTON-NORWICH PRODUCTS, INC. (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236039-B2 | Multi-step process for converting cyclic alkyleneureas into their corresponding alkyleneamines | ALKBH1, ALKBH3, ALKBH2 | KMT2A 529/4885MEN1 1361/4885FAAH 1162/4885 |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | KMT2A 742/4885MEN1 3176/4885FAAH 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.